|
| Friday, August 26, 2022 |
|
|
Sirnaomics推進基於GalAhead(TM)遞送平台的RNAi療法，用於治療補體介導相關疾病 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead(TM) RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. more info >> |
|
| Monday, August 22, 2022 |
|
|
Sirnaomics获纳入恒生指数系列成份股 |
| Sirnaomics Ltd.（“Sirnaomics”或“公司”，股份代号：2257.HK），一家行业领先的专注于探索及开发RNAi疗法的生物制药公司，宣布公司将获恒生指数有限公司纳入八个指数成份股 more info >> |
|
|
Sirnaomics獲納入恒生指數系列成份股 |
| Sirnaomics Ltd.（「Sirnaomics」或「公司」，股份代號：2257.HK），一家行業領先的專注於探索及開發RNAi療法的生物製藥公司，宣佈公司將獲恒生指數有限公司納入八個指數成份股 more info >> |
|
|
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has been selected as a constituent stock of eight index series including Hang Seng Composite Index ("HSCI") more info >> |
|
| Friday, August 19, 2022 |
|
|
Sirnaomics核心产品RNAi治疗药物STP705用于治疗面部原位鳞状细胞皮肤癌的I/II期临床试验完成首例受试者给药 |
| Sirnaomics Ltd.（“Sirnaomics”或“公司”，股份代号：2257.HK），一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics核心產品RNAi治療藥物STP705用於治療面部原位鱗狀細胞皮膚癌的I/II期臨床試驗完成首例受試者給藥 |
| Sirnaomics Ltd.（「Sirnaomics」或「公司」，股份代號：2257.HK），一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has dosed the first patient in a Phase I/II clinical study of STP705 more info >> |
|
| Tuesday, August 16, 2022 |
|
|
Sirnaomics研发用于优化GalNAc递送平台的肽对接载体（PDoV(TM)），致力于创新siRNA疗法 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics研發用於優化GalNAc遞送平台的肽對接載體（PDoV(TM)），致力於創新siRNA療法 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
|
|
